Article Text

Download PDFPDF
Use of troponins in clinical practice: Evidence against the use of troponins in clinical practice
  1. Mark Mariathas1,2,
  2. Nick Curzen1,2
  1. 1 Wessex Cardiac Unit, University Hospital Southampton NHS F Trust, Southampton, UK
  2. 2 Faculty of Medicine, University of Southampton, Southampton, UK
  1. Correspondence to Professor Nick Curzen, Wessex Cardiac Unit, University Hospital Southampton NHS F Trust, Southampton SO16 6YD, UK; nick.curzen{at}uhs.nhs.uk

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We have read with interest the paper by Collinson et al,1 and we are grateful for an opportunity to respond to their comments, especially those that relate to our recent BMJ paper describing the Is the current threshold for diagnosing raised highly sensitive troponin apparopriate for a hospital population? (CHARIOT) study.2

The use of more sensitive troponin assays in UK hospitals is now universal. The frontline clinical staff who request and then interpret the test belong to a wide range of clinical specialties. The concept for CHARIOT emerged out of our observations that there was an important mismatch in actual clinical practice between the extremely precise guidelines that lay out how these assays should be employed to rule out myocardial infarction (MI), or diagnose MI or myocardial injury, and their actual use. Specifically, there are important and widespread misconceptions about how troponin values should be or can be interpreted. First, that the manufacturer-provided 99th centile value for their assay represents a binary ‘upper limit of normal’ for a hospital population. Second, that a single troponin result above that 99th centile represents an ‘acute coronary syndrome’ diagnosis, regardless of whether there is an appropriate accompanying history. Third, that the general awareness that type 2 MI and myocardial injury are common, distinct clinical entities from type 1 MI, both pathophysiologically and in terms of appropriate management algorithms, …

View Full Text

Footnotes

  • Twitter @NickCurzen

  • Contributors This article was drafted by both listed authors.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles